a b s t r a c t Self-illuminating quantum dots, also known as QD-BRET conjugates, are a new class of quantum dot bioconjugates which do not need external light for excitation. Instead, light emission relies on the bioluminescence resonance energy transfer from the attached Renilla luciferase enzyme, which emits light upon the oxidation of its substrate. QD-BRET combines the advantages of the QDs (such as superior brightness and photostability, tunable emission, multiplexing) as well as the high sensitivity of bioluminescence imaging, thus holding the promise for improved deep tissue in vivo imaging. Although studies have demonstrated the superior sensitivity and deep tissue imaging potential, the stability of the QD-BRET conjugates in biological environment needs to be improved for long-term imaging studies such as in vivo cell tracking. In this study, we seek to improve the stability of QD-BRET probes through polymeric encapsulation with a polyacrylamide gel. Results show that encapsulation caused some activity loss, but significantly improved both the in vitro serum stability and in vivo stability when subcutaneously injected into the animal. Stable QD-BRET probes should further facilitate their applications for both in vitro testing as well as in vivo cell tracking studies.
Semiconductor quantum dots (QDs) have captivated scientists and engineers over the past two decades owing to their fascinating optical and electronic properties, which are not available from either single individual molecules or bulk solids [1] . Compared with organic dyes and fluorescent proteins, semiconductor QDs offer several unique advantages, such as size-and composition-tunable emission from visible to infrared wavelengths, large absorption coefficients across a wide spectral range, and very high levels of brightness and photostability [2] . These properties make them appealing fluorescent probes for bioimaging applications including in situ cell/tissue labeling, live cell imaging, and in vivo imaging [3] . However, in vivo imaging using quantum dots still faces challenges such as interferences from tissue autofluorescence [4] and paucity of light available at non-superficial tissue sites [5] . One approach to solve these problems is to use high quality nearinfrared (NIR) QDs [6] , which is an area still under active development. Alternatively, since both problems are related to the need for external excitation light, a ''self-illuminating" quantum dot that does not require external light to fluoresce may also help to alleviate these problems.
Recently, work in our laboratory has demonstrated the feasibility of using QDs as the acceptor in a bioluminescence resonance energy transfer (BRET) system [7] . BRET is a naturally occurring phenomenon whereby a light-emitting protein (the donor, e.g. R. reniformis luciferase) non-radiatively transfers energy to a fluorescent protein (the acceptor, e.g. green fluorescent protein) in close proximity. In this study, QDs were covalently conjugated by EDC (N-ethyl-N 0 -(3-dimethylaminopropyl)carbodiimide hydrochloride) coupling to the donor, Luc8 protein, an eight-mutation variant of the bioluminescent R. reniformis luciferase [8] . Upon the addition of substrate, coelenterazine, the protein emits blue light with a peak at 480 nm and this energy transfers to the QDs in close proximity, causing QDs to fluoresce. In this way, the need for an external excitation light source is eliminated. This ''self-illuminating" feature allows imaging in deeper tissue where light sources are limited. Compared with existing QDs, self-illuminating QD conjugates have greatly enhanced sensitivity in small animal imaging, with an in vivo signal-tobackground ratio of >1000 for 5 pmole of conjugate subcutaneously injected [7] . However, the stability of the first generation of QD-BRET probes in blood or serum is moderate, thus prohibiting many in vivo applications such as tumor targeting and cell trafficking. Mechanisms for deterioration in bioluminescence activity of QD-BRET probes are not clear; since the protein by itself is relatively stable in serum and the stability of the conjugates in the phosphate buffer is much better, some unfavorable interactions between the QD and protein, and inactivation of the protein by serum/blood proteins may both be responsible. In this work, we explored strategies to preserve the stability of the enzyme on the QD in order to achieve longer-lived QD-BRET probes and use them for prolonged animal imaging purposes. Enzyme stability improvement or how to preserve its activity under harsh conditions (such as high temperature, organic solvents, etc.) has been studied for a long time in the industrial biotechnology field. Complementary to genetic modifications such as directed evolution [9] and site mutation [10] , chemical modification via conjugation or encapsulation provides an efficient route to preserve enzyme stability under harsh conditions. Different coating materials have been tested including silica [11] , polymers [12, 13] , and organo-clay. These coating materials, however, may hinder the conformational transition of the enzyme and the transport of substrate, resulting in low biocatalytic activity. A few years ago, Kim and Grate reported an encapsulation scheme that does not cause significant increase in mass transfer resistance [14] . This scheme consists of multiple steps including surface modification, lyophilization, polymerization in organic solvent, and shell condensation. More recently, Yan et al. reported a new two-step procedure that involves surface acryloylation and in situ aqueous polymerization to encapsulate a single enzyme in a nanogel [15] . The authors applied this technique to both horseradish peroxidase and bovine carbonic anhydrase [15, 16] , and both showed excellent preservation of their biocatalytic activities (70-80%). Encouraged by these results, we applied this approach to improve the serum stability of QD-BRET conjugates. We characterized the optical properties of the encapsulated QD-BRET conjugates and evaluated their in vitro and in vivo stability.
Experimental procedures
Animals and imaging equipments. Nude mice (4-6 weeks old) were from Charles River Breeding Laboratories. Fluorescence and bioluminescence emission spectra were collected with a Fluoro Max-3 (Jobin Yvon Inc., NJ); in the case of bioluminescence, the excitation light was blocked, and emission spectra were corrected with a correction file provided by the company. Bioluminescence emission spectra collected with the spectrofluorometer were further corrected for the Luc8 kinetics over the course of data acquisition (typically 20 s). Enzymatic activity of Luc8 was measured with a 20/20 n Luminometer (Turner Biosystems, Inc.). Animal use protocols were reviewed and approved by the Institutional Animal Care Use Committee of Stanford University. Preparation of QD-Luc8 BRET probe. Quantum dots BRET probes were made according to a procedure published previously by our lab [7] . Briefly, carboxylated semiconductor quantum dots (QD655, Invitrogen) were mixed with coupling agent EDC (Fluka, 4000 equivalents to QDs) and Luc8 protein (20 equivalents to QDs) in phosphate buffer (pH 7.4) and reacted for 1 h at room temperature. Afterwards, excessive EDC and protein (MW: 37 kDa) were removed by ultrafiltration with a MWCO 100 K filter (Millipore) at 5000 rpm for 3 times at 4°C. The washed conjugates were then measured for bioluminescence and fluorescence using a Fluoro Max-3 Fluoremeter (Jobin Yvon). Each quantum dot has approximately six protein molecules on the surface.
Conjugates acryloylation and polymeric encapsulation. QD-Luc8 conjugates (100 pmole) were mixed with acryloylating agent acrylic acid N-hydroxysuccinimide ester (8 lg) and stabilizer 4-dimethylaminoantipyrine (2 lg) in borate buffer (100 mM, pH 9.3) and incubated at 30°C. This step converts free amines in the protein to vinyl groups. After 2 h reaction, excessive reagents (acrylic acid N-hydroxysuccinimide ester, 4-dimethylaminoantipyrine) were removed by gel filtration (G-25 column) or ultrafiltration filter (MWCO: 100 K, Millipore). The acryloylated conjugates were then purged with argon before adding in 3 ll TEMED (Bio-Rad) and ammonium persulfate (100 lg, Sigma). Subsequently, acrylamide monomer (Invitrogen) and cross-linking agent N,N 0 -methylene bis-acrylamide (Sigma) dissolved in deoxygenated water were evenly added to the solution over the next hour at a molar ratio of 10 to 1. Total amount of monomer added was approximately 5000 times of protein molecules present on the quantum dots. The mixture was left at room temperature under argon for another hour. At the end, excessive monomer and cross-linking reagents were removed from the conjugates by passing through a G-75 column or ultrafiltration (MWCO: 100 K).
TEM and dynamic light scattering. Sizing of the nanoparticles was achieved by dynamic light scattering (Brookhaven 90 plus nanosizer) and transmission electron microscopy. TEM specimens were prepared by pipetting 5 ll of the samples onto ultrathin Carbon Type A 400-mesh copper grids (Tedpella Inc., Redding, CA) that had been glow-discharged. After about 5 min, the grids were rinsed with deionized water to remove any buffer salts that may be present in the samples and wicked to almost dryness using filter paper. Phosphotungstic acid (PTA) at pH 7.0 was then added onto the grids to negatively stain the samples. After 1 min the grids were completely dried using filter paper. All the specimens were analyzed using a Philips CM20 FEG-TEM operated at 200 kV at the Stanford Nanocharacterization Laboratory (SNL). The microscope is also equipped with an energy dispersive X-ray spectrometer (EDS) for compositional analysis.
In vitro stability testing. QD-Luc8 conjugates obtained from above were incubated in equal-volume mouse serum (Equitech Bio.) at 37°C. The stability kinetics was checked by sampling at various time points (0, 24, 48, and 120 h). At each time point, the conjugates were measured for bioluminescence and quantum dot fluorescence (excitation: 480 nm).
Animal imaging. Quantum dot conjugates (5 pmole QDs) were injected subcutaneously into 4-6-week-old nude mice. The animals were then anesthetized with isoflurane and transferred into 
Results
Our modification procedure consists of two major steps: acryloylation of the protein and polymerization afterwards. The detailed procedure is shown schematically in Fig. 1 . Carboxylated quantum dots and Luc8 proteins were first conjugated by EDC coupling to produce the QD-BRET probes. After purification and removal of excessive reactants (protein and coupling agent), the probes were then incubated with acrylic acid N-hydroxysuccinimide ester in alkali buffer (100 mM borate buffer, pH 9.3) for 2 h at 30°C to generate surface vinyl groups. Encapsulation of each protein molecule was realized by in situ polymerization at room temperature with acrylamide as the monomer, N,N 0 -methylene bis-acrylamide as the cross-linker, and TEMED as the initiator for polymerization.
Conjugates size change after encapsulation
Dynamic light scattering results ( Fig. 2A and B) showed that, the encapsulated nanoparticles (effective diameter: 51.0 nm) were about twice as big as the unmodified conjugates (effective diameter: 26.0 nm). TEM results revealed that the size increase was mainly due to the cross-linking between the conjugates (Fig. 2C  and D) . Unmodified conjugates tend to remain as single particles or occasionally cross-linked to another nanoparticle (NP); the encapsulated conjugates are more likely to cross-link, therefore the hydrodynamic size is significantly bigger. This cross-linking in general took place among two to three NPs through the protein molecules, and the solubility and monodispersity of whole solution remains similar to the unmodified conjugates. Agrose gel analysis showed that the encapsulated conjugates moved slightly slower than the unmodified conjugates (Fig. 2G) .
Effect of encapsulation on BRET
QD-BRET probes after polymeric encapsulation were tested for fluorescence, bioluminescence and BRET (Fig. 2E and F) . The BRET ratio remained similar (1.33 vs. 1.32) after modification. Bioluminescence signal remained strong although a little attenuated as compared with unmodified conjugates (60%). The decrease in bioluminescence was mainly due to activity loss of Luc8 protein during the acryloylation step. This loss in activity can be controlled by adjusting the amount of acryloylating agent acrylic acid Nhydroxysuccinimide ester. For instance, increasing the molar ratio (acryloylating agent to protein) from low (4.6) to medium (9.3) and to high (93) will cause the remaining luciferase bioactivity to decrease by 20% (low) to 30% (medium) and 84% (high) of the unmodified protein, respectively. The following polymerization step did not cause any significant decline in the bioluminescence activity, regardless of the amount of monomer added (from 800 to 5000 per protein molecule).
Improvement of in vitro stability
In vitro serum stability results showed that polymeric encapsulation significantly improved the stability of QD-Luc8 conjugates (Fig. 3) . Unmodified conjugates lost their bioluminescence by 90-95% within 48 h in mouse serum at 37°C, while the encapsulated conjugates still had around 60% bioluminescence remaining during the same period of time. In fact, the encapsulated conjugates can stay in serum for up to 5 days, with still 37% bioluminescence remaining. Stored in phosphate buffer at 4°C, the encapsulated conjugates can last for over 4 months with significant amount of activity (>30%) remaining. There is also a sharp decline (from 1.33 to 0.07 within 48 h) in BRET ratio for the unmodified conju- gates, indicating disruption of the QD-Luc8 assembly in addition to the inactivation of the protein. In contrast, the encapsulated conjugates retained fairly good BRET ratio (1.32-0.73 after 48 h), suggesting the integrity of the conjugates was largely preserved. Lastly, QD stability (shown as the fluorescence excited by 480 nm) was also significantly improved by polymerization (Fig. 3) . It seems like the encapsulation not only protected the protein, but also helped to protect the whole assembly.
Improvement of in vivo stability
QD-Luc8 conjugates (encapsulated or unmodified, each at 5 pmole of QD as determined by the QD fluorescence) were injected subcutaneously in nude mice and bioluminescence and fluorescence images were captured at 6, 12, 24, 48, 72, 102, and 196 h post-injection (Fig. 4) . Results showed that encapsulated conjugates (left side) remained stable and active (bioluminescent) for much longer time inside living body than the unmodified control conjugates (right side) (Fig. 4) . Total bioluminescence signals (Fig. 4A, '' Bioluminescence imaging, open filter") from the unmodified conjugates became barely detectable at 48 h, while signals from encapsulated conjugates remained very strong at 72 h and remained detectable at 196 h. The BRET signal from the control conjugates disappeared after 24 h (Fig. 4A, ' 'Bioluminescence imaging, QD filter"), by contrast, the encapsulated conjugates showed strong BRET signal even at 72 h and remained detectable at 102 h (Fig. 4B,   Fig. 4 . A comparison of in vivo stability of encapsulated vs. unmodified QD-BRET conjugates. The two types of conjugates were injected subcutaneously into the same animal (left, encapsulated; right, unmodified) and monitored for QD bioluminescence (A and B) and fluorescence (C). Bioluminescence and BRET images were taken immediately after injection of coelenterazine; open filter collects light signals across the whole spectrum, and QD filter only collects light emitting between 650 and 660 nm. Graphs (B) show bioluminescence signals and BRET ratios changes over time; note that BRET ratios are smaller than in vitro measurement, because the BRET signals were only collected over 650-660 nm, instead of 600-750 nm as in vitro. QD fluorescence images were taken under excitation at 465 nm.
BRET ratio). The QD fluorescence inside living animal was also improved by polymeric encapsulation (Fig. 4C, fluorescence imaging) . Signals from the unmodified conjugates disappeared by 72 h; while signals from the encapsulated conjugates remained detectable after 196 h (8 days) post-injection.
Discussion
Due to their superior brightness and photostability, quantum dots have sparkled tremendous interests in the biological sciences community and have rapidly found their way into many applications including in vivo animal imaging [17, 18] . Even with their superior optical properties of QDs, the same challenges remain for optical imaging at non-superficial tissue sites, which are the presence of strong background autofluorescence and photon absorbance/scattering by living tissues. One approach to solve these problems is to use QDs emitting in the near-infrared window. However, even in the near-infrared range [19] , tissue autofluorescence still remains and reduces the signal-to-background ratio. Self-illuminating quantum dots have great potential as an in vivo imaging and sensitive detection probe. Compared to conventional QDs, it eliminates the need for fluorescent excitation light and takes advantage of QDs blue-increasing extinction coefficient, greatly reduces the high background caused by surface illumination and tissue autofluorescence, efficiently couples chemical energy with light energy, and finally, because energy transfer is resonant, and non-radiative, absorption of excitation photons by hemoglobin and other tissue pigments is virtually eliminated [20] . The first publication on QD-BRET provided convincing evidence that QD-BRET conjugates significantly outperform conventional QDs for in vivo imaging [7] . Since then, the QD-BRET probes already found several applications including live cell imaging [21, 22] and protease detection [23] . Despite all these attractive properties, broader and long time in vivo imaging applications have been thus far prohibited because of their relatively low stability inside living body. In this study, we seek to improve the stability of self-illuminating QDs through a polymeric encapsulation method. We adopted the procedure reported by Yan et al. [15] for its simplicity (only two steps) and compatibility in aqueous media, since treatment with organic solvents such as that reported by Kim and Grate [14] may result in the disruption of the QD-protein assembly and inactivation of the BRET donor-Luc8 protein.
Surface modification of the protein, Luc8, resulted in activity loss proportional to the degree of acryloylation; likely due to the fact that the lysine (which contain the free amines to be modified by) residues are important for Luc8 function [8] . On the other hand, if there is too little acryloylation, polymerization would not happen and the stability improvement is minimal. Therefore, we have optimized the amount of acryloylating reagents to retain reasonable activity of the enzyme but still achieve the stability improvement. Our experiments have shown that the polymerization step did not cause significant additional activity loss in the conjugates, indicating the polymer coating did not present much barrier for the substrate transport (data not shown). Our studies also showed that the amount of monomer needed (monomer: protein ratio of 5000) for enhanced stability is much higher than that reported by Yan et al.
(monomer: protein ratio of 400 to 800). Below this level, we did not observe any significant stability improvements. One possible reason is that proteins anchored on the surface of a nanoparticle may behave very differently from free proteins in solution. For instance, free Luc8 protein remained active for much longer time than those immobilized onto the QD surface. Additionally, our TEM data suggested cross-linking took place between the nanoparticles. Based on this, we expect cross-linking between protein molecules will take place on the same nanoparticle as well and we believe this inter-and inter-particle cross-linking responsible for the observed stability improvement.
There are at least two possible mechanisms that might account for improved stability of the encapsulated conjugates. First, the polymer coating acts as a physical barrier to large biomolecules such as proteases, thus keeping them from attacking the Luc8 protein on the QD surface. The second reason for improved stability is likely due to flexibility change of the protein molecules on the QD surface. Inter-and inner-nanoparticle cross-linking by the acrylamide/bis-acrylamide might have altered the flexibility of the protein and thus prevented them from conformational changes that may be detrimental to their activity.
Although the encapsulated conjugates outperformed the unmodified conjugates in both in vitro and in vivo (subcutaneous injection) studies, the advantages were not significant when they were systematically injected into the animals. Both types of conjugates were rapidly taken up by the reticuloendothelial system (RES) and degraded soon afterwards. RES uptake is a challenging issue with almost all kinds of nanostructures and it has been reported that surface chemistry of the nanostructure plays a critical role. Further engineering of the surface chemistry, for instance, attaching polyethylene glycol, may help alleviate this problem.
